Summary.-The sera from patients with advanced cancer were tested for their specific inhibitory effects on the cytotoxicity of autologous lymphocytes on tumour cells in a microculture assay. By adding a standard volume of the sera to suspensions of well-washed lymphocytes the inhibitory effect was quantitated by comparison with the effect of normal allogeneic serum. Significant levels of inhibitory activity were detected in 7 patients (one massive primary melanoma, 4 with disseminated melanoma, one with metastatic hypernephroma and one with a recurrent leiomyosarcoma). The patient with a massive primary melanoma was treated by extensive surgical excision. This procedure was associated with the rapid and complete disappearance of the serum inhibitory effect. In the other cases surgical intervention was minimal and the serum inhibitor was unaffected. All 6 of these patients were then immunized with irradiated autologous tumour cells and the serum inhibitory activity assayed. In 5 cases the serum inhibitor rapidly became undetectable after a single immunization. The one patient who failed to respond in this manner had very extensive disease and died within 2 weeks of the study. Repeated monthly immunization in the case of recurrent leiomyosarcoma was associated with the maintenance of the serum inhibitory activity at very low levels and with good cliiiical progress. The response to a single immunization is transient, the inhibitor becoming detectable again at 14-21 days. The possible role of circulating antigen in this serum inhibitory activity is discussed, as is the potential value of assaying the sera of cancer patients for serum inhibitory activity, as a means of monitoring the effects of treatment.
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IF immunological techniques are to be effective in the treatment of cancer, methods will be needed for assaying the reactions of patients to antigens on their own tumour cells and for monitoring the effects of treatment on these reactions. Hellstrom and her colleagues (1971) have shown that the peripheral blood lymphocytes from patients with a variety of tumours are capable of killing the appropriate target cells in tissue culture in a specific manner. Furthermore, they have indicated that the serum from these patients is capable of " blocking " this cytotoxic reaction in a similarly specific fashion. Currie and Basham (1972) have shown that the cytotoxic effects of peripheral blood lymphocytes from patients with advanced cancer were dramatically increased by extensive washing. Furthermore, this newly exposed cytotoxic effect was inhibited by the addition of the patients' serum to the lymphocyte suspension. There was also suggestive evidence for a clinical correlation between extent of disease and presence of this specific serum inhibitor. In patients with small primary malignant melanomata the serum inhibitor was undetectable whereas in those with large primary tumours or metastatic disease it was found readily. It was postulated that antigenic determi-nants from the cell surface are constantly being shed by a tumour and leak into the extracellular fluid and serum. There, possibly complexed with antibody or other proteins, such substances act as potent inhibitors of antitumour cellmediatedimmunereactions. Furthermore, the concentration of this inhibitory material in the peripheral blood may well reflect the extent of the disease and its presence in the serum might be of diagnostic value.
In earlier studies of the effects of autoimmunization of patients with disseminated melanoma with irradiated tumour cells we (Currie, Lejeune and Fairley, 1971 ) were able to demonstrate increases in the cytotoxic effects of their peripheral blood lymphocytes when tested on autologous tumour cells. These findings can be re-interpreted in view of the demonstration of specific serum inhibitors as showing that the immunization procedure had abolished, or at least reduced, the levels of circulating inhibitor.
This communication describes experiments which attempt to quantitate the effects of active immunization with irradiated tumour cells (with or without B.C.G.) on the serum inhibitory material in a small group of patients with disseminated cancer. (Sokal, Aungst and Han, 1972) . The preparation used was percutaneous vaccine (Glaxo), and the details of each case are listed in Table I . When B.C.G. was admixed with the autologous cell suspension the resulting vaccine was administered intradermally in one limb in 8 distinct sites.
RESULTS
The detailed results of the cytotoxicity assays are shown in Table II were not of adequate quality and therefore the lymphocytes were tested on allogeneic melanoma cultures. As indicated previously (Currie and Basham, 1972) the cytotoxic effects of the lymphocytes from melanoma patients cross-react on allogeneic melanoma cells. The inclusion in this study of normal allogeneic donors and the specificity controls continue to support earlier conclusions concerning the specificity of the reactions (Currie and Basham, 1972 All the patients studied had advanced disease. The inhibitory effects of their sera on autologous lymphocyte cytotoxicity were measured before immunization. The lymphocytes tested in this system were all subjected to extensive washing before use because of previous experience (Currie and Basham, 1972) which indicated that the lymphocytes from patients with extensive disease were cytotoxic only after such a washing step. Significant inhibition of the cytotoxic effects of autologous lymphocytes on the appropriate target cells was detected in all cases. The specificity of this inhibitory material was as described previously (Currie and Basham, 1972 Case LMS1 where it was measured at 14 days and thereafter at Days 28, 56 and 74. These results are shown in Table II andFig. 1. Day 0 is the day on which the immunization started. In all cases except one there was a dramatic fall in the serum inhibitory effect detectable after one week. In Case LMS1 the inhibitor had disappeared at Day 14. This was measured again at Day 28 when it had increased to 17%. Re-immunization at Days 28 and 56 was associated with the maintenance of his serum inhibitor at minimal levels.
The one exception to the effects of immunization was the case of hypernephroma (HYP 27). This patient had a large hypernephroma at the lower pole of his right kidney which was extensively invasive into the inferior vena cava, the duodenum and the retroperitoneal space. There were also lytic metastases in the ribs and lumbar vertebrae. The tumour Recognition of the existence of these serum inhibitoryfactors and theirapparent specificity to tumour type may have clinical implications. If, as seems probable, the antigens on tumours are specific to the organ of origin and totally crossreact between tumours of similar diagnosis, then the quantitative analysis of such antigenic material in the serum may be of value for the clinical management of cancer patients.
The present study has employed an in vitro method for the detection and quantitation of the serum inhibitory material in a small series of patients with advanced tumours. Serum inhibitory effects were detectable in all the cases. Following active immunotherapy with irradiated autologous tumour cells with or without B.C.G., the inhibitory activity was drastically reduced in all cases but one (HYP 27) . In this exceptional case there was, if anything, a rise in serum inhibitor which accompanied a dramatic decline in his clinical condition, with the growth of extensive metastatic disease. If, as we have postulated previously, circulating antigen is capable of inhibiting tumourdirected cell-mediated immunity then the addition of further tumour antigen, in the form of the tumour cell vaccine, may well add to an already overloaded pool of antigen and thus be unable to evoke any kind of imm'nological response. However, prediction of which case is likely to do this and which to respond favourably, with a decline in serum inhibitory activity, is at present impossible. The initial inhibitory effect of the Pay 0 serum in this case was extremely hikh and the patient's tumour burden was massive. His lack of response may have been dictated by the initial high level of inhibitory activity.
Sinkovics and his colleagues (Sinkovics, Cabiness and Shullenberger, 1972) have described three patients with disseminated sarcomata whose lymphocyte cytotoxicity and serum " blocking " factors were examined before and after treatment with cytosine arabinoside. All three possessed cytotoxic lymphocytes and serum " blocking " factors. Followingthe chemotherapy these inhibitors became undetectable although the cytotoxic effects of the lymphocytes were unaffected. In one case the disappearance of the serum inhibitor was associated with temporary tumour regression. Two of these patients had previously received irradiated allogeneic sarcoma cells as a form of immunotherapy but the authors did not report any effect of this procedure alone on the serum inhibitory activity. Sinkovics et al. (1972) postulated that the cytosine arabinoside had abolished " blocking activity " by interfering with the synthesis of specific antibody, thus preventing the formation of " blocking " immune complexes. These authors examined sera for this " blocking " activity by pre-incubation of the target cells with the test serum before addition of the lymphocytes, as do Hellstrom et al. (1971) in their assay system. Tested in this manner it is feasible that inhibitory effects would be detected only when specific antibody, probably complexed with antigen, was present. In our assay system the test serum is directly incorporated in the lymphocyte suspension and no pre-incubation step is involved. Thus it could be argued that, in the test format used by us, inhibitory activity of excess antigen, as well as immune complex would be detected. It is of interest that Sinkovics and his colleagues were able to detect " blocking " serum activity in only about half the cases of disseminated disease. It may well be that with progression of the tumours, with its attendant release of large quantities of tumour antigen, immune complexes would be overwhelmed and a condition of antigen excess would prevail, in which case the " blocking " activity may not be detectable in an assay in which the serum is pre-incubated with the target cells. Thus, in some patients with established disease the serum inhibitor may be circulating immune complex, whereas in those whlere the tumour burden is more massive it may be antigen relatively free of specific antibody and detectable only in assays in which the serum is included in the reaction mixture. Baldwin and his colleagues (Baldwin, Price and Robins, 1972) have emphasized the critical nature of the antigen-antibody ratio in immune complexes which determine their in vitro "blocking" activity, addition of excess antigen to tumour bearing serum abolishing its blocking activity. This blocking was assayed by pre-incubation of the target cells with the test serum. Excess antigen would tend to inhibit attachment of immunoglobulin receptor sites to the target cells and when the serum is discarded the potential inhibitory material is removed. It would seem rational to restrict the term " blocking" to findings obtained from the pre-incubation type of assay and to use the somewhat vague term "inhibition " to describe the effects obtained in our inclusion assay.
How does immunization with tumour cells lead to a reduction in serum inhibitory effect? Presumably when the patient is injected with tumour cells in a limb uninvolved by tumour the regional node chain is stimulated. Ikonopisov and his colleagues (1970) (Currie and Basham, 1972 (Ikonopisov et al., 1970; Currie et al., 1974 
